Gene therapies hold great promise in treating a wide range of genetic and acquired diseases.
However, current gene therapies are recognized as "dangerous" by the patient's immune system, leading to immune activation that results in low effectiveness and high toxicity.
At Crane Biosciences, we leverage red blood cell-derived nanoparticles (RBCNPs) to make gene therapies invisible to the immune system, preventing immune reactions and related issues.
Thanks to our proprietary AI platform, we are able to precisely target our invisible therapies to specific cells, ensuring minimal side effects and high efficacy.
Industrial engineer and biotechnologist, 2x founder, >$1.5Mn raised
PhD from the Francis Crick Institute, ten years working with RBCNPs
PhD from Vanderbilt University, seven years working with AI-powered drug design
Copyright © 2022 Crane Biosciences - All rights reserved.